SLC5A2 and infection: Concerning the development of urogenital infection during the treatment with SGLT2 inhibitors, in contrast to euglycemic ketoacidosis for which temporary discontinuation is advised, routine discontinuation of SGLT2 inhibitors in the setting of urogenital infections is not recommended; SGLT2 inhibitors should be continued in mild–moderate and clinically stable severe infections, while their discontinuation might be necessary for the setting of life-threatening infections when the risks significantly exceed the benefits [56].